文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

卵圆孔未闭偏头痛患者抗血栓治疗的多中心随机对照试验

Antithrombotic treatment for migraine in patients with patent foramen ovale: multicentre, randomised, active controlled, open label trial.
PubMed 文献 · BMJ · 2026-07-29

该研究纳入1000例18-64岁、偏头痛病史超过1年且每月至少4天偏头痛、经超声心动图确诊卵圆孔未闭的成人,随机分配至阿司匹林、氯吡格雷、利伐沙班或美托洛尔治疗12周。主要终点为每月偏头痛天数或发作次数较基线减少≥50%的应答率,三种抗血栓药对美托洛尔均非劣效,利伐沙班应答率显著更高且未增加大出血事件。

要点

  • 阿司匹林、氯吡格雷、利伐沙班对美托洛尔在偏头痛应答率上均非劣效。
  • 利伐沙班应答率78.4%,较美托洛尔绝对差异16.2%(98.33%CI 6.0-26.4,P<0.001)。
  • 利伐沙班在减少偏头痛天数、发作次数及完全停止方面优于美托洛尔,无大出血。

核心结论

  • 在卵圆孔未闭合并偏头痛患者中,阿司匹林、氯吡格雷和利伐沙班对美托洛尔的偏头痛应答率均非劣效。
  • 利伐沙班应答率显著优于美托洛尔,且未增加大出血事件。

研究设计与样本

  • 研究者发起的多中心、前瞻性、随机、活性对照、开放标签临床试验,采用盲法结局评估和分层假设检验。
  • 中国39个中心二级和三级医院参与,纳入1000例18-64岁偏头痛超过1年、每月至少4天偏头痛且超声心动图确诊卵圆孔未闭的成人。
  • 随机前完成12周筛选期,排除既往卒中、短暂性脑缺血发作、颅内出血、非卵圆孔未闭右向左分流或研究药物禁忌者;984例(75.1%女性)纳入全分析集。
  • 按1:1:1:1随机接受阿司匹林300 mg每日一次、氯吡格雷75 mg每日一次、利伐沙班20 mg每日一次或美托洛尔25 mg每日两次,治疗12周,期间不允许额外预防性偏头痛治疗。

主要发现

  • 主要终点应答率:阿司匹林61.7%(148/240)、氯吡格雷66.8%(157/235)、利伐沙班78.4%(185/236)、美托洛尔61.8%(144/233)。
  • 利伐沙班较美托洛尔应答率绝对差异16.2%(98.33%CI 6.0至26.4;P<0.001)。
  • 次要终点中,利伐沙班较美托洛尔在减少偏头痛天数与发作次数、提高完全停止率及改善偏头痛特异性生活质量评分方面更优。
  • 未发生大出血事件。

关键数值与推荐

  • 主要终点为从基线至第9-12周每月偏头痛天数或发作次数减少≥50%的参与者比例。
  • 非劣效判定:阿司匹林、氯吡格雷和利伐沙班对美托洛尔均非劣效。
  • 利伐沙班应答率78.4%,美托洛尔61.8%,绝对差异16.2%(98.33%CI 6.0至26.4;P<0.001)。

临床怎么用

  • 对于卵圆孔未闭合并偏头痛且符合入组特征的患者,可考虑抗血栓治疗作为偏头痛预防选项。
  • 利伐沙班在应答率及多项次要终点上优于美托洛尔,且未增加大出血,但需结合个体出血风险评估。
  • 阿司匹林和氯吡格雷可作为非劣效替代选择。

局限性

  • 开放标签设计,尽管采用盲法结局评估。
  • 干预时长仅12周,长期疗效与安全性未报告。
  • 排除既往卒中、短暂性脑缺血发作、颅内出血等患者,外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of antithrombotic treatment for migraine prevention in participants with patent foramen ovale (PFO). DESIGN: Investigator initiated, multicentre, prospective, randomised, active controlled, open label clinical trial with blinded outcome assessment and hierarchical hypothesis testing. SETTING: Secondary and tertiary care hospitals across 39 centres in China. PARTICIPANTS: 1000 adults aged 18-64 years with a diagnosis of migraine for more than one year, experiencing at least four migraine days per month, and with PFO confirmed by echocardiography. All participants completed a 12 week screening period before randomisation during which eligibility was confirmed and baseline headache data were prospectively recorded. Participants with previous stroke, transient ischaemic attack, intracranial haemorrhage, non-PFO right-to-left shunt, or contraindications to study drugs were excluded. Of the randomised participants, 984 (75.1% female) were included in the full analysis set. INTERVENTIONS: After the screening phase, participants were randomised in a 1:1:1:1 ratio to receive aspirin (300 mg once daily), clopidogrel (75 mg once daily), rivaroxaban (20 mg once daily), or metoprolol (25 mg twice daily) for 12 weeks. No additional preventive migraine treatments were permitted during the intervention period. MAIN OUTCOME MEASURES: The primary outcome was the proportion of participants achieving a ≥50% reduction in monthly migraine days or attacks from baseline to weeks 9-12. Safety outcomes included bleeding and other adverse events. RESULTS: For the primary endpoint, aspirin, clopidogrel, and rivaroxaban were all non-inferior to metoprolol. Responder rates were 61.7% (148/240) with aspirin, 66.8% (157/235) with clopidogrel, 78.4% (185/236) with rivaroxaban, and 61.8% (144/233) with metoprolol. Rivaroxaban further showed a statistically higher responder rate than metoprolol, with an absolute difference of 16.2% (98.33% confidence interval 6.0 to 26.4; P<0.001). Among secondary endpoints, rivaroxaban was associated with greater reductions in migraine days and attacks, higher rates of complete migraine cessation, and greater improvements in migraine specific quality-of-life scores than metoprolol. No major bleeding events occurred. CONCLUSIONS: The antithrombotic agents evaluated in this trial (aspirin, clopidogrel, and rivaroxaban) were all non-inferior to metoprolol for responder rate in participants with PFO and migraine. Rivaroxaban also showed superior responder rates over metoprolol without an increase in major bleeding events. TRIAL REGISTRATION: ClinicalTrials.gov NCT05546320.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Li Z, Wang C, Tang Y, et al. Antithrombotic treatment for migraine in patients with patent foramen ovale: multicentre, randomised, active controlled, open label trial. BMJ. 2026. PMID: 42526943. doi:10.1136/bmj-2026-100103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。